Levels of a protein believed to be a main cause of Alzheimer’s disease rose in the blood of patients treated with Eli Lilly’s experimental drug in late-stage trials, suggesting the protein, beta amyloid, was removed from the brain as intended, researchers said on Monday.
Lilly in August disclosed that its drug solanezumab did not significantly arrest progression of the memory-robbing disease in the pair of Phase III studies, which tested patients with mild to moderate symptoms of Alzheimer’s.
